The published new data on the predictive power of Electronic Health Records (using an AI algorithm) in combination with the biomarkers sTNFR 1 & 2 and KIM-1 (all components of Renalytix AI’s KidneyIntelX™ test for rapidly progressing kidney disease) provides a strong indication of clinical utility. As an illustration, the positive predictive value reached an impressive 53% in the test group of Type II diabetes patients classified as High Risk. In our view, the results bode well for the read-out ....
01 Apr 2019
New published data supportive for KidneyIntelX™ development
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
New published data supportive for KidneyIntelX™ development
Renalytix Plc (RENX:LON) | 30.0 0 0.0% | Mkt Cap: 37.9m
- Published:
01 Apr 2019 -
Author:
Jens Lindqvist -
Pages:
4
The published new data on the predictive power of Electronic Health Records (using an AI algorithm) in combination with the biomarkers sTNFR 1 & 2 and KIM-1 (all components of Renalytix AI’s KidneyIntelX™ test for rapidly progressing kidney disease) provides a strong indication of clinical utility. As an illustration, the positive predictive value reached an impressive 53% in the test group of Type II diabetes patients classified as High Risk. In our view, the results bode well for the read-out ....